KCNQ2-related epilepsy spans a continuum from self-limited familial neonatal epilepsy to severe neonatal-onset developmental and epileptic encephalopathy. KCNQ2 encodes the Kv7.2 potassium-channel subunit, a major regulator of neuronal excitability.
Self-limited and severe disease can involve the same gene
At the mild end, otherwise healthy newborns develop seizures in the first week of life that remit during infancy.
At the severe end, seizures begin in the neonatal period and are accompanied by markedly abnormal EEG, movement abnormalities and substantial developmental impairment.
Self-limited familial neonatal epilepsy
Classic KCNQ2 self-limited neonatal epilepsy usually begins between days 2 and 8 after term birth.
Seizures often include tonic stiffening, focal motor activity, apnoea or cyanosis and usually stop within the first year.
KCNQ2 neonatal-onset DEE
Severe KCNQ2-DEE typically presents with multiple daily seizures in the first week of life.
EEG may show burst suppression or multifocal epileptiform activity, and developmental disability can remain severe even after seizures improve.
Why the phenotypes differ
Different variants alter Kv7.2 function to different degrees.
Milder familial disease commonly involves inherited variants, whereas severe DEE is often caused by de novo variants with stronger dominant-negative or other disruptive effects.
EEG
The self-limited phenotype can have a normal background between seizures.
Severe DEE can show burst suppression, multifocal abnormalities or marked slowing.
MRI
MRI can be normal in self-limited disease.
Severe KCNQ2-DEE may show basal-ganglia abnormalities early and later white-matter or cerebral-volume loss in some individuals.
Treatment
Self-limited neonatal seizures may respond to conventional neonatal antiseizure treatment and can sometimes remit rapidly.
In severe KCNQ2-DEE, seizure control is often more difficult.
Sodium-channel blockers
GeneReviews and cohort evidence indicate that sodium-channel blockers can be particularly effective in KCNQ2 neonatal-onset DEE.
This is an important example of a genetic epilepsy where molecular diagnosis may influence treatment choice.
Development beyond seizures
People with severe KCNQ2-DEE can have hypotonia, spasticity, movement disorders, limited speech and major cognitive impairment.
Seizure freedom does not necessarily reverse the underlying developmental disorder.
Later seizures
A proportion of people with the self-limited phenotype develop febrile seizures or epilepsy later in childhood, adolescence or adulthood.
The term self-limited refers to the neonatal epilepsy syndrome, not guaranteed lifelong seizure freedom.
Inheritance
Self-limited familial neonatal epilepsy is usually autosomal dominant and inherited.
Severe neonatal-onset DEE is more often de novo.
Precision medicine research
Because KCNQ2 affects the neuronal M-current, therapies designed to enhance Kv7 channel activity are an area of interest.
Some mechanism-specific approaches remain experimental or have limited clinical evidence.
Worldwide access
KCNQ2 is among the more common single-gene causes of neonatal epilepsy, making rapid genetic testing particularly valuable.
Where genomic testing is unavailable, diagnosis depends on age at onset, EEG, family history and exclusion of acute neonatal causes.
The central point
KCNQ2 can cause either a self-limited neonatal epilepsy or a severe lifelong developmental disorder. The gene result must always be interpreted alongside the clinical phenotype.
Related reading
Self-Limited Neonatal Epilepsy →
Early Infantile DEE →
Sources
Medical note: neonatal seizures have many urgent causes. Genetic diagnosis should complement, not replace, acute neonatal evaluation.
Evidence checked: September 2026.